Chi-Med’s Sinopharm Deal Opens Doors To China Market For Partners, CEO Says
This article was originally published in PharmAsia News
The joint venture allows the newly formed subsidiary Hutchison Sinopharm to sell pharmaceuticals all over China and become a “super partner” for multinationals selling medicines in the country.
You may also be interested in...
SciClone Pharmaceuticals will significantly broaden its commercial footprint across China by acquiring privately owned, Shanghai-based specialty pharma NovaMed Pharmaceuticals for close to $62 million plus potential earnouts in a deal that closed April 18
Suzhou-based Innovent Bio becomes the fourth biotech from mainland China to go public in Hong Kong, and its strong first-day performance may have given the seemingly spooked market so far for such companies a shot of confidence.
A rapidly reforming policy and regulatory environment and a growing culture of innovation are encouraging capital and talent to pour into China, making it a question of when, rather than if, the payoffs will come for both consumers and investors.